Stockreport

BioCardia outlines imminent CardiAMP FDA submission and targets regulatory catalysts as trial data signals clinical benefit [Seeking Alpha]

BioCardia, Inc.  (BCDA) 
PDF Peter Altman, CEO, highlighted that BioCardia now has complete and final data from three clinical trials of CardiAMP cell therapy, with the latest Phase III results pre [Read more]